TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24559814

Group type: EXPERIMENTAL
Intervention: Topical Trikatu preparation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Reference product (camphor, menthol, eucalyptus)
Number of subjects: 30
Study: 23061989

Group type: EXPERIMENTAL
Intervention: Sitagliptin + metformin
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo + metformin
Number of subjects: 178
Study: 19728035

Group type: EXPERIMENTAL
Intervention: Transdermal estrogen patch 0.1 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg/day to 100 mg/day for 9 weeks
Number of subjects: 0
Study: 18023899

Group type: EXPERIMENTAL
Intervention: Rotational atherectomy
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Directional atherectomy
Number of subjects: 266

Group type: COMPARATOR
Intervention: Non-debulking (rotational)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Non-debulking (directional)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Debulking (combined)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Non-debulking (combined)
Number of subjects: 266
Study: 17664519

Group type: EXPERIMENTAL
Intervention: Intervention group (cognitive-behavioral therapy and pharmacological management)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 206

Group type: COMPARATOR
Intervention: Usual-care group (Control)
Number of subjects: 206
Study: 14967388

Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Fallopian tube sperm perfusion (FSP)
Number of subjects: 56
Study: 10914616

Group type: EXPERIMENTAL
Intervention: Soy isoflavone extract (50 mg genistin and daidzin per day)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study: 9180289

Group type: EXPERIMENTAL
Intervention: low-dose Ara-C with growth factors
Number of subjects: 45

Group type: COMPARATOR
Intervention: low-dose Ara-C without growth factors
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Patients without clonal markers at diagnosis
Number of subjects: 45
Study: 1564502

Group type: EXPERIMENTAL
Intervention: New intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Old intervention
Number of subjects: 0
Study: 2436505

Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suxamethonium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcuronium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D-tubocurarine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pancuronium
Number of subjects: 0
Study: 31630990

Group type: EXPERIMENTAL
Intervention: Adjuvanted inactivated vaccine
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: All vaccine regimens
Number of subjects: 65

Group type: COMPARATOR
Intervention: Intramuscular study product or placebo
Number of subjects: 65

Group type: COMPARATOR
Intervention: Intranasal study product or placebo
Number of subjects: 65

Group type: COMPARATOR
Intervention: Study product or placebo
Number of subjects: 65
Study: 31198066

Group type: EXPERIMENTAL
Intervention: 4-week mindfulness intervention
Number of subjects: 36

Group type: COMPARATOR
Intervention: Breathing control
Number of subjects: 36
Study: 28365035

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 27009046

Group type: EXPERIMENTAL
Intervention: Morita Therapy plus treatment as usual
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment as usual alone
Number of subjects: 60
Study: 24311443

Group type: EXPERIMENTAL
Intervention: HT (conjugated estrogens, 0.625 mg/d)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/d)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 23101534

Group type: EXPERIMENTAL
Intervention: Handle position 2
Number of subjects: 50
Study: 19950737

Group type: EXPERIMENTAL
Intervention: Diclofenac patch (180 mg of diclofenac epolamine salt)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 126
Study: 17325399

Group type: EXPERIMENTAL
Intervention: Young age of self and partner at first intercourse
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-use of contraception at first intercourse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Use of contraception at first intercourse
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Young partner at first intercourse
Number of subjects: 0
Study: 15142019

Group type: EXPERIMENTAL
Intervention: High-intensity eccentric PRT (HRT)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Low-intensity eccentric PRT (LRT)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control
Number of subjects: 37
Study: 11566277

Group type: EXPERIMENTAL
Intervention: Topical application of 160 mg/g methyl 5-aminolevulinate for 3 hours
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Topical application of 16 mg/g methyl 5-aminolevulinate for 3 or 18 hours
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Topical application of 80 mg/g methyl 5-aminolevulinate for 3 or 18 hours
Number of subjects: 16
Study: 9591168

Group type: EXPERIMENTAL
Intervention: Multimodal pain treatment program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (fibromyalgia patients who failed to qualify for the treatment program)
Number of subjects: 0
Study: 7886773

Group type: EXPERIMENTAL
Intervention: Artemisinin plus mefloquine
Number of subjects: 544

Group type: COMPARATOR
Intervention: Artemisinin alone for 5 d
Number of subjects: 544

Group type: COMPARATOR
Intervention: Artemisinin plus sulfadoxine-pyrimethamine (SP)
Number of subjects: 544

Group type: COMPARATOR
Intervention: Mefloquine-sulfadoxine-pyrimethamine (MSP)
Number of subjects: 544

Group type: COMPARATOR
Intervention: Quinine plus sulfadoxine-pyrimethamine (SP)
Number of subjects: 544
Study: 2980870

Group type: EXPERIMENTAL
Intervention: The Eating Machine software
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EATS software
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ferguson's behavioral program alone
Number of subjects: 0
Study: 28926514

Group type: EXPERIMENTAL
Intervention: 0.003% estradiol vaginal cream (15 μg estradiol; 0.5 g cream) applied daily for 2 weeks followed by three applications/week for 10 weeks
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: 0.003% estradiol vaginal cream
Number of subjects: 550

Group type: COMPARATOR
Intervention: Placebo (0.5 g cream)
Number of subjects: 550
Study: 27286071

Group type: EXPERIMENTAL
Intervention: Work-focused cognitive-behavioural therapy plus convergence dialogue meeting (CDM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Work-focused cognitive-behavioural therapy without CDM
Number of subjects: 60
Study: 25329643

Group type: EXPERIMENTAL
Intervention: Modified version of the stabilization device (MVSD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-moving ambulance (NM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moving ambulance without device (MND)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moving ambulance with device (MD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: All conditions
Number of subjects: 0
Study: 23881566

Group type: EXPERIMENTAL
Intervention: Umeclidinium (100-1,000 μg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Umeclidinium (500 μg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Umeclidinium (1,000 μg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 20528791

Group type: EXPERIMENTAL
Intervention: Facilitation through group meetings at local health centres with health staff and community key persons
Number of subjects: 17519

Group type: COMPARATOR
Intervention: Home deliveries without skilled attendance
Number of subjects: 17519
Study: 18932120

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - Actively advised to apply for medical rehabilitation with individual risk information.
Number of subjects: 471

Group type: COMPARATOR
Intervention: Control Group (CG) - Received usual care.
Number of subjects: 471
Study: 17054472

Group type: EXPERIMENTAL
Intervention: 50 mg DHEA
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: DHEA withdrawal
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (male patients)
Number of subjects: 26
Study: 12154110

Group type: EXPERIMENTAL
Intervention: Normal sodium diet (108 mmol/d NaCl)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low sodium diet (20 mmol/d NaCl)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: In vitro sodium concentrations (154 to 308 mmol/L)
Number of subjects: 12
Study: 10195508

Group type: EXPERIMENTAL
Intervention: High thoracic epidural anesthesia (TEA)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Intravenous clonidine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (general anesthesia only)
Number of subjects: 70
Study: 8560359

Group type: EXPERIMENTAL
Intervention: 100 mg nitrofurantoin macro-crystals 3 times daily for 7 days (Group A)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: 100 mg nitrofurantoin macro-crystals 4 times daily for 7 days (Group B)
Number of subjects: 101
Study: 2127940

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (1 gram of cefotetan)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 266
Study: 536982

Group type: EXPERIMENTAL
Intervention: Geriatric screening and surveillance
Number of subjects: 295
Study: 31619441

Group type: EXPERIMENTAL
Intervention: e-cigs containing 50% propylene glycol and 50% vegetable glycerine
Number of subjects: 30

Group type: COMPARATOR
Intervention: no-use control group
Number of subjects: 30
Study: 31815651

Group type: EXPERIMENTAL
Intervention: Saline-filled balloon inserted above the main joint of the shoulder at the end of arthroscopic debridement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adaptive designs
Number of subjects: 0
Study: 28371941

Group type: EXPERIMENTAL
Intervention: Mirogabalin 15 mg/day
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Mirogabalin 20 mg/day
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Mirogabalin 30 mg/day
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Mirogabalin (all doses)
Number of subjects: 452

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 452
Study: 25863985

Group type: EXPERIMENTAL
Intervention: High-fat meals consumed during four weeks
Number of subjects: 0
Study: 24078432

Group type: EXPERIMENTAL
Intervention: Management of fetal growth restriction (TRUFFLE trial)
Number of subjects: 503
Study: 21419678

Group type: EXPERIMENTAL
Intervention: Bangerter filters (0.2 and 0.3 filters)
Number of subjects: 186
Study: 19272597

Group type: EXPERIMENTAL
Intervention: 300 mL water intake
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: 400 mL water intake
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: 500 mL water intake
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 93
Study: 17320555

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass
Number of subjects: 989

Group type: COMPARATOR
Intervention: Percutaneous coronary intervention
Number of subjects: 989
Study: 15328306

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg) administered 5 hours before exercise trial
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo administered 5 hours before exercise trial
Number of subjects: 8
Study: 11887898

Group type: EXPERIMENTAL
Intervention: Rholida
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Xi's capsule
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 9557471

Group type: EXPERIMENTAL
Intervention: Pefloxacin 800 mg i.v. slow infusion
Number of subjects: 297

Group type: COMPARATOR
Intervention: Ceftriaxone 2 g i.v.
Number of subjects: 297
Study: 8231752

Group type: EXPERIMENTAL
Intervention: Prone immersion (WET)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standing upright on land (DRY)
Number of subjects: 12
Study: 3524439

Group type: EXPERIMENTAL
Intervention: 6.5% tioconazole ointment
Number of subjects: 80

Group type: COMPARATOR
Intervention: 100 mg clotrimazole vaginal tablets (3-day course)
Number of subjects: 80
Study: 30067077

Group type: EXPERIMENTAL
Intervention: 2s:4s (n = 18)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 10s:10s (n = 20)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 30s eccentric, 30s concentric, and 30s eccentric (e.g., 1.5 repetitions; n = 21)
Number of subjects: 59
Study: 27545191

Group type: EXPERIMENTAL
Intervention: Aprepitant plus ondansetron and prednisone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ondansetron and prednisone (Control)
Number of subjects: 0
Study: 25935645

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT) with topotecan and cisplatin
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy with consolidation chemotherapy (CCRT + CT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Radiotherapy only (RT)
Number of subjects: 39
Study: 22999784

Group type: COMPARATOR
Intervention: Extended Sprint (ES)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sprint Interval Training (SIT)
Number of subjects: 10
Study: 21640258

Group type: EXPERIMENTAL
Intervention: VEGF Trap-Eye 2 mg every 4 weeks during the fixed-dosing phase
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: VEGF Trap-Eye (all groups combined)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: VEGF Trap-Eye (after 12-week fixed-dosing phase)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: VEGF Trap-Eye
Number of subjects: 159
Study: 19811592

Group type: EXPERIMENTAL
Intervention: Omission of the misleading detail from the vignette
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Asking doctors to identify a leading diagnostic detail and formulate an alternative diagnosis after omission of the detail
Number of subjects: 51

Group type: COMPARATOR
Intervention: Warning doctors about potentially misleading information
Number of subjects: 51
Study: 17034605

Group type: EXPERIMENTAL
Intervention: Intensive pelvic floor muscle therapy (PFMT)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Vaginal cone therapy
Number of subjects: 238

Group type: COMPARATOR
Intervention: Primary behavioral intervention (control)
Number of subjects: 238
Study: 15165091

Group type: EXPERIMENTAL
Intervention: Talc (5 g)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Quinacrine (500 mg)
Number of subjects: 110
Study: 11261275

Group type: EXPERIMENTAL
Intervention: High dose chemotherapy (HDCT) with autologous stem cell transplantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study: 9373483

Group type: EXPERIMENTAL
Intervention: Topical diclofenac sodium
Number of subjects: 64

Group type: COMPARATOR
Intervention: No diclofenac
Number of subjects: 64
Study: 1535051

Group type: EXPERIMENTAL
Intervention: Goserelin (3.6 mg every 4 weeks)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Symptomatic therapy
Number of subjects: 33
Study: 4028987

Group type: EXPERIMENTAL
Intervention: Four 0.1 mg doses of fenoterol each at 30 minute intervals
Number of subjects: 11

Group type: COMPARATOR
Intervention: Single dose of 0.4 mg fenoterol aerosol
Number of subjects: 11
Study: 2441920

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other DMARD
Number of subjects: 0
Study: 31034350

Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide (G1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 37% carbamide peroxide (G2)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Comparison between G1 and G2 at one month
Number of subjects: 50
Study: 27660163

Group type: EXPERIMENTAL
Intervention: Bimonthly intravitreal injections of ranibizumab (IVR)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Bimonthly intravitreal injections of aflibercept (IVA)
Number of subjects: 26
Study: 26312955

Group type: COMPARATOR
Intervention: Codeine/acetaminophen for 10 days post‐tonsillectomy (5 days scheduled, followed by 5 days as‐needed)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Tramadol for 10 days post‐tonsillectomy (5 days scheduled, followed by 5 days as‐needed)
Number of subjects: 74
Study: 23984631

Group type: EXPERIMENTAL
Intervention: Cognitive ability
Number of subjects: 138
Study: 21504262

Group type: EXPERIMENTAL
Intervention: Telehealth system with case management (THCM)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Case management (CM)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Overall population (both groups)
Number of subjects: 316
Study: 18043495

Group type: EXPERIMENTAL
Intervention: Active Noise Reduction (ANR) headphone audiometry
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard audiometry
Number of subjects: 37
Study: 16434130

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 148

Group type: COMPARATOR
Intervention: No BCG vaccination (control group)
Number of subjects: 148
Study: 12921245

Group type: EXPERIMENTAL
Intervention: Meropenem 0.5 g every 8 hours as a 3-hour infusion
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Meropenem 2 g every 8 hours as a 3-hour infusion
Number of subjects: 6
Study: 10866910

Group type: EXPERIMENTAL
Intervention: Placebo + GBP (600 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Morphine (60 mg) + GBP (600 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo + placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Morphine + placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Morphine + GBP
Number of subjects: 12
Study: 9378841

Group type: EXPERIMENTAL
Intervention: 250 mg of caffeine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 500 mg of caffeine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7505434

Group type: EXPERIMENTAL
Intervention: gammaglobulin 150 mg/kg x 2 on the first day of admission
Number of subjects: 54

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: gammaglobulin 300 mg/kg/die for 3 days
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: gammaglobulin 150 mg/kg/die during hospitalization
Number of subjects: 54
Study: 3885107

Group type: EXPERIMENTAL
Intervention: Ceftizoxime 2-g dose at cord clamping
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 31236976

Group type: EXPERIMENTAL
Intervention: TVT-O (transobturator sling)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: TVT-S (single-incision sling)
Number of subjects: 94

Group type: COMPARATOR
Intervention: TVT-O
Number of subjects: 94

Group type: COMPARATOR
Intervention: TVT-S
Number of subjects: 94
Study: 28241355

Group type: EXPERIMENTAL
Intervention: Testosterone gel for 12 months
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo gel for 12 months
Number of subjects: 170
Study: 25732625

Group type: EXPERIMENTAL
Intervention: Beloranib 0.6 mg
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Beloranib 1.2 mg
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Beloranib 2.4 mg
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 23088807

Group type: EXPERIMENTAL
Intervention: EVLA810-1 (810-nm axial diode laser with 4-F introducer, 0.018" guidewire, 22-G needle)
Number of subjects: 60

Group type: COMPARATOR
Intervention: RFA (ClosureFAST)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: EVLA1470 (1470-nm radial diode laser)
Number of subjects: 60
Study: 22106845

Group type: EXPERIMENTAL
Intervention: Group relaxation training sessions according to the Yoga in Daily Life(®) system, plus audiocassette recordings for 3 weeks at home.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard physiotherapy for 1 week (control group).
Number of subjects: 32
Study: 19142129

Group type: EXPERIMENTAL
Intervention: Anterior chamber reformation with balanced salt solution and concurrent drainage of choroidal effusion
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Anterior chamber reformation with viscoelastic substance
Number of subjects: 36

Group type: COMPARATOR
Intervention: Pharmacologic therapy with atropine, phenylephrine, and in select cases oral acetazolamide
Number of subjects: 36
Study: 18181342

Group type: EXPERIMENTAL
Intervention: Cisplatin at 80 mg/m2 and irinotecan at 200 mg/m2 on day 1, followed by docetaxel at 75 mg/m2 on day 22, in 6-week cycles for a maximum of 3 cycles.
Number of subjects: 24
Study: 15383054

Group type: EXPERIMENTAL
Intervention: Contegra bovine valved jugular vein conduit
Number of subjects: 108
Study: 12512683

Group type: EXPERIMENTAL
Intervention: Polyaminopropyl biguanide (PHMB) -based system
Number of subjects: 50

Group type: COMPARATOR
Intervention: Polyquad (polyquaternium-1) -based system
Number of subjects: 50
Study: 9801234

Group type: EXPERIMENTAL
Intervention: Fibular fixation
Number of subjects: 0

Group type: COMPARATOR
Intervention: No fibular fixation
Number of subjects: 0
Study: 8542099

Group type: EXPERIMENTAL
Intervention: Chronic intermittent intravenous insulin therapy (CIIIT)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Intensive subcutaneous insulin therapy (ISIT) alone
Number of subjects: 74
Study: 2477813

Group type: EXPERIMENTAL
Intervention: Carbon-tip electrode (Siemens-Elema 412 S, tip material vitreous carbon)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Platinum-tip electrode (Siemens-Elema 415 S, tip material platinum)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Carbon-tip electrode
Number of subjects: 79

Group type: COMPARATOR
Intervention: Platinum-tip electrode
Number of subjects: 79
Study: 205687

Group type: EXPERIMENTAL
Intervention: Zoster immune plasma (ZIP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control plasma (lacking varicella-zoster virus antibodies)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No transfusions
Number of subjects: 20
Study: 30681196

Group type: EXPERIMENTAL
Intervention: Nocturnal stimulation with a pleasant odor (odor condition) via an olfactometer or odorized nasal clip
Number of subjects: 40

Group type: COMPARATOR
Intervention: Clean air (placebo condition) via an olfactometer
Number of subjects: 40
Study: 28601733

Group type: EXPERIMENTAL
Intervention: SRP + 1.2% simvastatin gel
Number of subjects: 46

Group type: COMPARATOR
Intervention: SRP
Number of subjects: 46
Study: 26493253

Group type: EXPERIMENTAL
Intervention: Passeo-18 Lux DEB (paclitaxel-coated drug-eluting balloon)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Passeo-18 PTA (uncoated balloon)
Number of subjects: 72